EKF Diagnostics Holdings PLC Purchase of Own Shares (8483G)
01 4월 2022 - 3:00PM
UK Regulatory
TIDMEKF
RNS Number : 8483G
EKF Diagnostics Holdings PLC
01 April 2022
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Purchase of Own Shares
Further to the confirmation of its intention to implement a
share buyback programme, as set out in its announcement on 29 March
2022 , the Company announces that it has purchased a total of
750,000 of its ordinary shares at a price of 44.1667 pence per
share. The ordinary shares purchased will be held in treasury.
Aggregated information
Date of purchase 31 March 2022
Number of ordinary shares purchased 750,000
--------------
Highest price paid per share 44.4
--------------
Lowest price paid per share 44
--------------
Volume weighted average price
paid 44.1667
--------------
Transaction details
In accordance with Article 5(1)(b) of Regulation (EU) No
596/2014 (the Market Abuse Regulation) (which forms part of
domestic UK law pursuant to the European Union (Withdrawal) Act
2018) , a detailed breakdown of individual trades is available
below:
Number of ordinary Transaction price Time of transaction Trading venue
shares purchased (GBp)
400,000 44 16:11:44 AIMX
------------------ -------------------- --------------
150,000 44.3 12:26:53 AIMX
------------------ -------------------- --------------
200,000 44.4 08:22:57 AIMX
------------------ -------------------- --------------
Total voting rights
Following the purchase, the Company's total issued share capital
will consist of 463,930,564 ordinary shares of 1 pence each
("Ordinary Shares") each carrying one voting right, of which
2,950,000 Ordinary Shares are held in treasury. Therefore, the
total number of Ordinary Shares carrying voting rights will be
460,980,564. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
Enquiries:
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Mike Salter, CEO via Walbrook PR
Marc Davies, CFO
Singer Capital Markets (Nominated Adviser
and Joint Broker)
Aubrey Powell / George Tzimas / Tom
Salvesen +44 (0)20 7496 3000
Investec Bank plc (Joint Broker)
Gary Clarence / Daniel Adams +44 (0)20 7597 4000
Walbrook PR Limited +44 (0)20 7933 8780 or ekf@walkbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0)7980 541 893 /
+44 (0)7584 391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading global diagnostics business with custom manufacturing
facilities across sites in the US, UK and Europe for a variety
of life science products. EKF is focussed on the following
areas:
Point-of-Care Providing a portfolio Point-of-Care analysers
and consumables, particularly for use in the
area of Hematology and Diabetes, for use in
hospital and research laboratories, doctor's
offices, blood banks and for in-field anaemia
screening programmes. EKF has an estimated 80,000
hemoglobin, hematocrit, HbA1c, glucose and lactate
analysers in regular use across more than 100
countries.
Central Laboratory Clinical chemistry, Small lab analysers, Centrifuges
Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor,
Glycates Albumin, Glycated Serum Protein, Nitro-tab,
Procalcitonin
Life Sciences Enzyme fermentation, Custom products and Bulk
fermentation
Contract Manufacturing Bulk formulation, Sample collection kits, Private
labelling, Molecular and forensic kits
Laboratory Services In September 2021, EKF completed the acquisition
of Advanced Diagnostic Laboratory LLC ("ADL
Health") , a Texas based testing laboratory
certified under the Clinical Laboratory Improvement
Amendments ("CLIA") for high complexity testing.
The laboratory provides testing for a variety
of clinical, forensic and microbiological sample
types using a range of analytical techniques.
This acquisition positions EKF as a leading
'one stop' provider of diagnostic products and
services from sample collection to results.
In May 2021, EKF announced its strategy for delivering growth
to 2024 and beyond, and continuing to deliver shareholder
value. The strategy for growth can be summarised as:
* continuing innovation in products and services in
Point-of-Care, Central Laboratory and Life Sciences
leveraging new and existing routes to market and
relationships;
* investment in expanded production and kitting
capabilities to offer a suite of diagnostic Contract
Manufacturing solutions to third party businesses;
* expansion of CLIA Laboratories Testing offering
building on the acquired capabilities in ADL Health;
and
* identify complementary earnings-enhancing
acquisitions with key strategic value.
EKF will also continue to generate enhanced shareholder value
through:
* a progressive dividend policy; and
* its agreement with Mount Sinai Innovation Partners
("MSIP"), which allows us advanced access to
innovative commercial opportunities and where we can
build on the ongoing successes of Renalytix plc,
Verici Dx plc and Trellus Health plc.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
POSBKDBNABKDFNN
(END) Dow Jones Newswires
April 01, 2022 02:00 ET (06:00 GMT)
EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
